Andres Felipe Florez

Medico Internista
Creador de contenida digital educativo

[Annals of Int Med @AnnalsofIM]

A new living clinical guideline from @ACPIMPhysicians recommends #semaglutide and #tirzepatide as first-line options when initiating pharmacologic treatment with lifestyle modifications for weight management for nonpregnant adults with obesity. Read the full guideline: https://t.co/1Tbu4z60Kh

[Medscape @Medscape]

Could factor XIa (FXIa) inhibition change the future of secondary stroke prevention?

Hear experts discuss the science behind FXIa targeting and review key phase 2 and 3 trial data shaping this emerging approach to care.

▶️ https://t.co/uFr3A5jhde

[Gastroenterology & Endoscopy News @gastroendonews]

The FDA has approved the first treatment for chronic hepatitis Delta virus (HDV): bulevirtide-gmod (Hepcludex).
Phase 3 data showed:
🔹 48% combined response at week 48 & more: https://t.co/bCYXPgSg08 #HDV

[American College of Cardiology @ACCinTouch]

Research presented at #ERA26 highlighted new findings in chronic kidney disease (CKD), including evidence supporting more precise GFR assessment & trial results on finerenone in nondiabetic CKD & rivaroxaban in advanced CKD patients w/ CV risk factors. 👇 https://t.co/p4LQ9X9fh4

[American College of Cardiology @ACCinTouch]

Survodutide led to significant weight loss in adults with obesity and without diabetes, according to results from the randomized, placebo-controlled SYNCHRONIZE-1 trial.

Learn more ➡️ https://t.co/6Mo4K4bzUn #CardioX

[NEJM @NEJM]

A new review of the evolving management of differentiated thyroid cancer highlights overdiagnosis of low-risk disease, dynamic risk stratification, active surveillance or ablation, targeted therapies, and active patient involvement.

Read the Review Article “Management of Differentiated Thyroid Cancer” by Laszlo Hegedüs, MD, Lori J. Wirth, MD, and R. Michael Tuttle, MD: https://t.co/0YKtWvwIEo

Try asking AI Companion to break this article down into teaching points for you.

[Gastroenterology & Endoscopy News @gastroendonews]

GLP-1s are gaining traction in #MASLD and #MASH treatment.
New studies show:
🔹 Semaglutide improves MASH resolution
& more
More options may soon reshape liver disease care: [article-linik] #GLP1 #Hepatology

https://t.co/ms0xHEbRsC

[American College of Cardiology @ACCinTouch]

VitaK-CAC: Supplementation with the vitamin K homologue menaquinone-7 significantly attenuated coronary artery calcification compared with placebo in adults with symptomatic #cvCAD.

Get full details ➡️ https://t.co/7gBxg0pA5A #CardioX

[Cardiology Today @CardiologyToday]

🗝️ takeaways:
💉 Coadministration of #COVID19 and flu #vaccines may reduce MACE and mortality risk vs. flu vaccination alone
❤️ Risk reduction was strongest among older adults with comorbidities
@InfectDisNews @HealioPulm

https://t.co/iIVtoyYiLJ

[Heart_BMJ @Heart_BMJ]

Myocardial infarction with non-obstructive coronary arteries: a pathway to achieve guideline adherence https://t.co/aLVVZTtWIF

[ASN Publications @asnpublications]

Potassium: target or surrogate of optimized care in heart failure? Perspective in #ASNJASN argues that the POTCAST trial may reflect MRA intensification more than potassium targeting. https://t.co/d7aQI5OQpz

[Nature Reviews Nephrology @NatRevNeph]

Sequential therapeutic approach for the management of osteoporosis in people with chronic kidney disease https://t.co/yZWZrG3EFF

[EHJ Editor-in-Chief @ehj_ed]

A new definition of MINOCA: from infarction
to injury. https://t.co/bIKCDyXaAG A new @EHJ paper proposes a vital update to #MINOCA: Myocardial Injury (not Infarction) with Non-Obstructive Coronary Arteries. This shift perfectly captures the "working diagnosis" phase, preventing premature diagnostic labels before advanced imaging confirms the actual cause. @ESCardio @ESC_Journals #NonObstructiveCoronaryArteries

[YO_ID @YO_ID_0722]

Pulmonary Fungal Infections in the Immunocompetent Host

@journal_CHEST

https://t.co/iE1LVfJ69C

[Dr. FEVI🫀🩺 @javier20ch]

Hipertensión Arterial en un punto de inflexión. 📈🫀👌🏻
🔷️La hipertensión está entrando en una nueva era: objetivos más agresivos y terapias dirigidas a mecanismos específicos. 👨‍⚕️🔎
🎯 Nuevas metas de TA:
✅ Las guías AHA/ACC 2025 establecen un objetivo universal de <130/80 mmHg.
✅ En pacientes con alto riesgo CV, se recomienda intentar alcanzar una PAS <120 mmHg, siempre que sea tolerado.
🎯Evitar mala adherencia, usar 2 fármacos de primera lina en una sola tableta desde estadio 2 (≥140/90 mmHg). 💊
🎯Nuevas vías terapéuticas:💊💉
1️⃣ Antagonismo dual de endotelina (Aprocitentan).
2️⃣ Inhibidores de la aldosterona sintasa (Lorundrostat y Baxdrostat).
3️⃣ RNA silenciador contra angiotensinógeno (Zilebesiran).
4️⃣ Denervación renal.
5️⃣ Obesidad & HAS (iGLP-1/GIP, Cx Bariatrica).

📄🆓️⤵️✨️State-Of-The-Art Review 2026 @JACCJournals 💯
https://t.co/Kgn9z2kNfD
https://t.co/oktV6loc8j

[Heart_BMJ @Heart_BMJ]

Present state and future of screening for atrial fibrillation: a state-of-the-art review #AFib #AF

https://t.co/OTk83wRO86

[Gastroenterology & Endoscopy News @gastroendonews]

Can a probiotic improve IBS symptoms?
At Digestive Disease Week 2026, Bifidobacterium longum NCC3001 improved:
📉 bloating
📉 abdominal pain
📈 quality of life
Read more: https://t.co/TBJ2n4O18r
#DDW2026 #IBS

[AJKD @AJKDonline]

Obesity in CKD: Core Curriculum 2026

https://t.co/zH9CjtaBwS (FREE)

@kramer_holly

[Blood Journals Portfolio @BloodPortfolio]

NEW in Blood Advances: @ASH_hematology / @isth 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism. Explore here ➡️ https://t.co/hf70Wd69Ge #BloodAdvances #ClinicalGuidelines #VTE

[NEJM @NEJM]

In the SNAP trial, cefazolin was noninferior to flucloxacillin or cloxacillin with respect to 90-day mortality in patients with methicillin-susceptible Staphylococcus aureus bacteremia and had fewer nephrotoxic effects. Read the full trial results and Research Summary: https://t.co/5Z39siPUhS